3D printed bilayer tablet with dual controlled drug release for tuberculosis treatment
Ghanizadeh Tabriz, Atabak, Nandi, Uttom, Hurt, Andrew, Hui, Ho-Wah, Karki, Shyam, Gong, Yuchuan, Kumar, Sumit and Douroumis, Dionysios ORCID: https://orcid.org/0000-0002-3782-0091 (2020) 3D printed bilayer tablet with dual controlled drug release for tuberculosis treatment. International Journal of Pharmaceutics, 593:120147. ISSN 0378-5173 (doi:10.1016/j.ijpharm.2020.120147)
Preview |
PDF (AAM)
36005_DOUROUMIS_3D_printed_bilayer_tablet.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (4MB) | Preview |
Abstract
In this study Fusion Deposition Modelling (FDM) was employed to design and fabricate a bilayer tablet consisting of isoniazid (INZ) and rifampicin (RFC) for the treatment of tuberculosis. INZ was formulated in hydroxypropyl cellulose (HPC) matrix to allow drug release in the stomach (acidic conditions) and RFC was formulated in hypromellose acetate succinate (HPMC – AS) matrix to allow drug release in the upper intestine (alkaline conditions). This design may offer a better clinical efficacy by minimizing the degradation of RFC in the acidic condition and potentially avoid drug-drug interaction. The bilayer tablet was prepared by fabricating drug containing filaments using hot melt extrusion (HME) coupled with the 3D printing. The HME and 3D printing processes were optimized to avoid drug degradation and assure consistent deposition of drug-containing layers in the tablet. The invitro drug release rate was optimized by varying drug loading, infilling density, and covering layers. Greater than 80% of INZ was released in 45 mins at pH 1.2 and approximately 76% of RFC was releases in 45 mins after the dissolution medium was changed to pH 7.4. The work illustrated the potential application of FDM technology in the development of oral fixed dose combination for personalized clinical treatment.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | 3D printing; oral solid dosage forms; controlled release; isoniazid; rifampicin; tuberculosis |
Subjects: | Q Science > QA Mathematics > QA75 Electronic computers. Computer science R Medicine > RS Pharmacy and materia medica |
Faculty / School / Research Centre / Research Group: | Faculty of Engineering & Science Faculty of Engineering & Science > Centre for Innovation and Process Engineering in Research (CIPER) Faculty of Engineering & Science > School of Science (SCI) |
Last Modified: | 06 May 2022 16:30 |
URI: | http://gala.gre.ac.uk/id/eprint/36005 |
Actions (login required)
View Item |
Downloads
Downloads per month over past year